Endurance training increases skeletal muscle LKB1 and PGC-1alpha protein abundance: effects of time and intensity

Autor: Jeremy D Lamb, Eric B. Taylor, Brian B Porter, David G Chesser, Lyle J. Greenwood, William W. Winder, William J Ellingson, Richard W. Hurst, Seth T. Herway

Publikováno v: American journal of physiology. Endocrinology and metabolism. 289(6)

Recent research suggests that LKB1 is the major AMP-activated protein kinase kinase (AMPKK). Peroxisome-proliferator-activated receptor-gamma coactivator-1alpha (PGC-1alpha) is a master coordinator of mitochondrial biogenesis. Previously we reported

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ab8238bbdd9d0d5f12ae00668cad579
https://pubmed.ncbi.nlm.nih.gov/16014350

Real-World Implementation of Simulation-Free Radiation Therapy (SFRT-1000): A Propensity Score-Matched Analysis of 1000 Consecutive Palliative Courses Delivered in Routine Care.

Autor: Schuler T; Department of Radiation Oncology, Northern Sydney Cancer Centre, Royal North Shore Hospital, Sydney, New South Wales, Australia; Australian Institute of Health Innovation, Macquarie University, Sydney, New South Wales, Australia. Electronic address: thilo.schuler@health.nsw.gov.au., Roderick S; Department of Radiation Oncology, Northern Sydney Cancer Centre, Royal North Shore Hospital, Sydney, New South Wales, Australia., Wong S; Department of Radiation Oncology, Northern Sydney Cancer Centre, Royal North Shore Hospital, Sydney, New South Wales, Australia., Kejda A; Department of Radiation Oncology, Northern Sydney Cancer Centre, Royal North Shore Hospital, Sydney, New South Wales, Australia., Grimberg K; Department of Radiation Oncology, Northern Sydney Cancer Centre, Royal North Shore Hospital, Sydney, New South Wales, Australia., Lowe T; Department of Radiation Oncology, Northern Sydney Cancer Centre, Royal North Shore Hospital, Sydney, New South Wales, Australia., Kipritidis J; Department of Radiation Oncology, Northern Sydney Cancer Centre, Royal North Shore Hospital, Sydney, New South Wales, Australia; Institute of Medical Physics, School of Physics, University of Sydney, Sydney, New South Wales, Australia., Back M; Department of Radiation Oncology, Northern Sydney Cancer Centre, Royal North Shore Hospital, Sydney, New South Wales, Australia; Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia., Bergamin S; Department of Radiation Oncology, Northern Sydney Cancer Centre, Royal North Shore Hospital, Sydney, New South Wales, Australia; Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia., Carroll S; Department of Radiation Oncology, Northern Sydney Cancer Centre, Royal North Shore Hospital, Sydney, New South Wales, Australia; Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia., Hruby G; Department of Radiation Oncology, Northern Sydney Cancer Centre, Royal North Shore Hospital, Sydney, New South Wales, Australia; Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia., Jayamanne D; Department of Radiation Oncology, Northern Sydney Cancer Centre, Royal North Shore Hospital, Sydney, New South Wales, Australia; Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia., Kneebone A; Department of Radiation Oncology, Northern Sydney Cancer Centre, Royal North Shore Hospital, Sydney, New South Wales, Australia; Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia., Lamoury G; Department of Radiation Oncology, Northern Sydney Cancer Centre, Royal North Shore Hospital, Sydney, New South Wales, Australia; Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia., Morgia M; Department of Radiation Oncology, Northern Sydney Cancer Centre, Royal North Shore Hospital, Sydney, New South Wales, Australia., Stevens M; Department of Radiation Oncology, Northern Sydney Cancer Centre, Royal North Shore Hospital, Sydney, New South Wales, Australia., Brown C; NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia., Gallego B; Centre for Big Data Research in Health, University of New South Wales, Sydney New South Wales, Australia., Porter B; Department of Radiation Oncology, Northern Sydney Cancer Centre, Royal North Shore Hospital, Sydney, New South Wales, Australia., Booth J; Department of Radiation Oncology, Northern Sydney Cancer Centre, Royal North Shore Hospital, Sydney, New South Wales, Australia; Institute of Medical Physics, School of Physics, University of Sydney, Sydney, New South Wales, Australia., Eade T; Department of Radiation Oncology, Northern Sydney Cancer Centre, Royal North Shore Hospital, Sydney, New South Wales, Australia; Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.

Publikováno v: International journal of radiation oncology, biology, physics [Int J Radiat Oncol Biol Phys] 2024 Sep 29. Date of Electronic Publication: 2024 Sep 29.

Automation and artificial intelligence in radiation therapy treatment planning.

Autor: Jones S; Radiation Oncology Princess Alexandra Hospital Raymond Terrace, Brisbane, Queensland, Australia., Thompson K; Department of Radiation Therapy Services, Peter MacCullum Cancer Care Centre, Melbourne, Victoria, Australia., Porter B; Northern Sydney Cancer Centre, Royal North Shore Hospital, Sydney, New South Wales, Australia., Shepherd M; Northern Sydney Cancer Centre, Royal North Shore Hospital, Sydney, New South Wales, Australia.; Monash University, Clayton, Victoria, Australia., Sapkaroski D; Department of Radiation Therapy Services, Peter MacCullum Cancer Care Centre, Melbourne, Victoria, Australia.; RMIT University, Melbourne, Victoria, Australia., Grimshaw A; W.P Holman Clinic, Royal Hobart Hospital, Hobart, Tasmania, Australia., Hargrave C; Radiation Oncology Princess Alexandra Hospital Raymond Terrace, Brisbane, Queensland, Australia.; Queensland University of Technology, Faculty of Health, School of Clinical Sciences, Brisbane, Queensland, Australia.

Publikováno v: Journal of medical radiation sciences [J Med Radiat Sci] 2024 Jun; Vol. 71 (2), pp. 290-298. Date of Electronic Publication: 2023 Oct 04.

Secukinumab and Sustained Reduction in Fatigue in Patients With Ankylosing Spondylitis: Long-Term Results of Two Phase III Randomized Controlled Trials.

Autor: Kvien TK; Diakonhjemmet Hospital and University of Oslo, Oslo, Norway., Conaghan PG; University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, UK., Gossec L; Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique and Pitié Salpêtrière Hospital, APHP, Paris, France., Strand V; Stanford University School of Medicine, Palo Alto, California., Østergaard M; Rigshospitalet, Glostrup, and University of Copenhagen, Copenhagen, Denmark., Poddubnyy D; Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin and German Rheumatism Research Centre, Berlin, Germany., Williams N; RTI Health Solutions, Durham, North Carolina., Porter B; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey., Shete A; Novartis Pharma AG, Basel, Switzerland., Gilloteau I; Novartis Pharma AG, Basel, Switzerland., Deodhar A; Oregon Health and Science University, Portland.

Publikováno v: Arthritis care & research [Arthritis Care Res (Hoboken)] 2022 May; Vol. 74 (5), pp. 759-767. Date of Electronic Publication: 2022 Mar 10.

Nonsteroidal anti-inflammatory drug-sparing effect of secukinumab in patients with radiographic axial spondyloarthritis: 4-year results from the MEASURE 2, 3 and 4 phase III trials.

Autor: Dougados M; Department of Rheumatology, Université de Paris, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France. maxime.dougados@aphp.fr.; INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France. maxime.dougados@aphp.fr., Kiltz U; Rheumazentrum Ruhrgebiet, Herne, Germany.; Ruhr Universität, Bochum, Germany., Kivitz A; Altoona Center for Clinical Research, Duncansville, USA., Pavelka K; Department of Rheumatology, Institute of Rheumatology, Prague, Czech Republic., Rohrer S; Novartis Pharma AG, Basel, Switzerland., McCreddin S; Novartis Ireland Ltd, Dublin, Ireland., Quebe-Fehling E; Novartis Pharma AG, Basel, Switzerland., Porter B; Novartis Pharmaceuticals Corporation, East Hanover, USA., Talloczy Z; Novartis Pharmaceuticals Corporation, East Hanover, USA.

Publikováno v: Rheumatology international [Rheumatol Int] 2022 Feb; Vol. 42 (2), pp. 205-213. Date of Electronic Publication: 2021 Nov 13.